Clinical Trial

Using Mirabegron to Control Arrhythmia-1

Study acronym: MACH-1
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-29.
Trial Details
NCT Number NCT07566208
Lead Sponsor Cedars-Sinai Medical Center
Conditions Ventricular Arrhythmias and Cardiac Arrest
Enrollment 20 participants
Start Date 2026-05
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-06